All Updates

All Updates

icon
Filter
Funding
Nabla Bio raises USD 26 million in Series A funding; signs three Big Pharma deals
AI Drug Discovery
May 14, 2024
This week:
M&A
Funding
TravelPerk raises USD 135 million in debt funding for expansion; acquires AmTrav
Travel Tech
Yesterday
Product updates
Apple announces Apple Pay Later shutdown
Buy Now, Pay Later
Jun 17, 2024
Management news
Velo3D appoints Brad Kreger as permanent CEO
Additive Manufacturing
Jun 17, 2024
Partnerships
Perplexity partners with SoftBank for AI search engine promotion in Japan
Generative AI Applications
Jun 17, 2024
Product updates
Runway launches Gen-3 Alpha for generating video clips
Generative AI Applications
Jun 17, 2024
Product updates
Adobe integrates Firefly into Acrobat with chat support across multiple documents in Acrobat AI Assistant
Generative AI Applications
Jun 17, 2024
Funding
Amplify Life raises USD 20 million in Series B to expand product suite
InsurTech: Personal Lines
Jun 17, 2024
Funding
Tinybird raises USD 30 million in Series B funding to improve real-time data analytics platform
Data Infrastructure & Analytics
Jun 17, 2024
Partnerships
The EVERY Company collaborates with Grupo Palacios to develop hen-less omelets
Plant-based Dairy & Egg
Jun 17, 2024
Partnerships
Believer Meats partners with AGWA to propel cultivated meat industry in MENA region
Cell-cultured Meat
Jun 17, 2024
AI Drug Discovery

AI Drug Discovery

May 14, 2024

Nabla Bio raises USD 26 million in Series A funding; signs three Big Pharma deals

Funding

  • Massachusetts-based antibody drug developer Nabla Bio has raised USD 26 million in a Series A round led by Radical Ventures, with contributions from all existing investors. It also announced partnerships with AstraZeneca, Bristol Myers Squibb Company, and Takeda, with potential earnings surpassing USD 550 million in upfront and milestone payments and royalties.

  • Nabla Bio plans to use the acquired funds to accelerate its drug development efforts, focusing primarily on antibodies targeting multipass membrane proteins. The capital will go toward the company’s research in creating solutions for hard-to-drug targets and complex cellular processes.

  • Nabla Bio is a biotech company that leverages AI to design antibodies for challenging diseases. The company's AI platform combines AI with massively parallel experimentation to design antibody therapeutics, primarily targeting complex multipass membrane proteins like G protein-coupled receptors (GPCRs) and ion channels.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.